Our interdisciplinary team of scientists collaborates to develop nanovaccines and nanotherapeutics

We are developing a universal influenza nanovaccine that would be effective against more strains of flu than current flu shots

For cancers, we are researching tumor-specific targets for nanotherapeutics

Nanovaccines can prevent tropical diseases such as malaria and filariasis

Nanotherapeutics use lower dosages than systemic drugs, allowing life-saving drugs to be used for young children

Nanoparticles can deliver therapeutic agents across the blood-brain barrier to treat neural disorders such as Alzheimer's, Parkinson's, and traumatic brain injury

No needles, no boosters: extended-release nanovaccines can be delivered by nasal inhaler rather than injection

Nanovaccines don't need refrigeration (polio campaign worker in India carrying styrofoam cooler for vaccine)

Nanoparticles average only 300 nanometers in diameter, 1000 times smaller than the period at the end of a sentence.

Our nanovaccine consortium is a diverse, interdisciplinary team (group photo at our June 2018 annual meeting at University of Iowa)